The European Medicines Agency (EMA) has concluded the consultation phase for its reflection paper on the application of Article 40(5) of Regulation (EU) 2019/6, which pertains to specific variations in veterinary medicinal products (VMPs). Key stakeholders, including Access VetMed and AnimalhealthEurope, provided comprehensive feedback addressing the clarity and implementation of the proposed regulatory criteria.
Stakeholder Concerns Highlight Need for Clarity
Access VetMed praised the EMA’s efforts to establish more detailed scientific criteria, aiming for consistency and predictability in regulatory processes. However, the organization expressed apprehension regarding the ambiguity in assessing variations, fearing it might lead to reduced competition in the VMP market. AnimalhealthEurope echoed similar sentiments, describing the EMA’s interpretation of Article 40(5) as overly restrictive and questioning the feasibility of meeting certain criteria without extensive data.
Quantitative vs. Qualitative Assessments Under Scrutiny
A central debate revolves around the EMA’s preference for quantitative risk assessments. While Access VetMed supports the emphasis on measurable parameters for assessing improvements or reductions in risk, concerns were raised about the practicality of obtaining sufficient data, especially for long-established reference products. The reflection paper indicates that, in many cases, risk assessments will remain qualitative, with quantitative data used selectively based on specific criteria.
- Stakeholders seek clearer guidelines on the necessary documentation for variation applications.
- There is a call for pre-submission meetings to discuss eligibility and criteria fulfillment.
- Concerns about the potential market impact and competition restrictions were voiced.
- Questions remain on how to quantify meaningful risk reductions effectively.
The EMA addressed some of these concerns by reiterating that the reflection paper serves to communicate ongoing discussions rather than provide exhaustive regulatory guidance. It emphasized that decision-making will remain on a case-by-case basis, considering the specific circumstances of each application.
Looking forward, the EMA plans to incorporate the feedback received to refine the regulatory framework. This iterative process aims to balance the need for stringent evaluation of VMPs with the practical challenges faced by applicants in meeting the specified criteria. The agency also highlighted the importance of evolving scientific knowledge in shaping future guidelines.
For stakeholders navigating the regulatory landscape, the key takeaway is the importance of early and clear communication with the EMA. Engaging in pre-submission discussions and thoroughly preparing documentation can enhance the likelihood of meeting the regulatory requirements under Article 40(5).
The ongoing dialogue between the EMA and industry stakeholders underscores the complex interplay between regulation and innovation in the veterinary pharmaceutical sector. As the EMA continues to refine its approach, stakeholders must stay informed and engaged to effectively contribute to and benefit from the evolving regulatory environment.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
